Jaka jest cena za Theralase Technologies Inc. (TLT)

Cena za Theralase Technologies Inc. (TLT) wynosi $0.13944801

Jaka jest kapitalizacja rynkowa dla Theralase Technologies Inc. (TLT)

Kapitalizacja rynkowa dla Theralase Technologies Inc. (TLT) wynosi $41.23M

Theralase Technologies Inc. (TLT) Marża Operacyjna

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.

Rok	Marża operacyjna	Zmień
Za mało danych dla podanych dat.

Rok

Marża operacyjna

Zmień

Za mało danych dla podanych dat.

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
Abbott Laboratories ABT.US	17.03%	-	US
Stryker Corporation SYK.US	22.03%	-	US
Medtronic plc MDT.US	17.86%	-	IE
Boston Scientific Corporation BSX.US	21.46%	-	US
Siemens Healthineers AG SHL.DE	0.00%	-	DE

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj